7月17日，ImmunityBio盘中下跌5.11%，报7.335美元/股，成交额3217.43万美元。消息面上，美股生物医药板块在过去一个月累计上涨约25%后持续承压，资金从高贝塔小盘生物科技股向大市值防御型药企的结构性轮动仍在延续。当日行业内艾伯维涨3.38%、吉利德涨2.72%、安进涨3.16%，大盘股表现强势，进一步印证分化格局。ImmunityBio作为年内涨幅较大的小盘标的，在无新增基本面利空的情况下连续回撤，系板块集中获利了结的缩影。
ImmunityBio是一家综合性免疫治疗公司，核心产品Anktiva已在全球33个国家获批上市，用于膀胱癌及肺癌治疗。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.